PARASHLTH vs SYMBIOTEC: Stock Comparison
SYMBIOTEC PHARMALAB is the larger company by market capitalisation. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
PARASHLTH leads 0; SYMBIOTEC leads 0 of 4
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | PARASHLTH | SYMBIOTEC |
|---|---|---|
| Live Price | ₹734.55 | ₹1,513.6 |
| Day Change | -5.12% | 19.04% |
| Volume | 4.08 L | 75.4 L |
| 52-Week High | ₹794.4 | ₹1,309.9 |
| 52-Week Low | ₹706 | ₹934.2 |
| Distance from 52W High | -7.53% | 15.55% |
Valuation
| Metric | PARASHLTH | SYMBIOTEC |
|---|---|---|
| Market Cap | ₹7,931 Cr | ₹9,799 Cr |
| EPS | — | ₹2.24 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | PARASHLTH | SYMBIOTEC |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | — | 0% |
| Qtr Profit Growth | — | 0% |
Profitability & Leverage
| Metric | PARASHLTH | SYMBIOTEC |
|---|---|---|
| Net Margin | 0% | 0% |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | PARASHLTH | SYMBIOTEC |
|---|---|---|
| Promoter Holding | — | 33.28% |
| FII Holding | — | 3.79%▼ 17.29 pp |
| DII Holding | — | 33.17%▲ 5.65 pp |
| Public Holding | — | 29.76%▲ 11.64 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: PARAS HEALTHCARE and SYMBIOTEC PHARMALAB.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.